Nitisinone

22 interactions

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Deuruxolitinib Acyclovir Acyclovir Injection Meropenem Injection Famotidine Injection Oseltamivir

1 Contraindicated 21 Major

All (22) Contraindicated (1) Major (21)

Contraindicated

Nitisinone Deuruxolitinib Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details

Major

Nitisinone Acyclovir Avaclyr Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Acyclovir Injection Avaclyr Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Acyclovir Ophthalmic Avaclyr Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Acyclovir Topical Zovirax Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Azathioprine Azasan An increased risk of hepatotoxicity Details Nitisinone Aztreonam Injection Azactam Increased risk of aztreonam exposure Details Nitisinone Baricitinib Olumiant Increased baricitinib exposure Details Nitisinone Cefaclor Ceclor® Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Erdafitinib Balversa Increased erdafitinib exposure Details Nitisinone Famotidine Calmicid Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Famotidine Injection Calmicid Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Furosemide Injection Disal Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Glipizide Glucotrol Increased CYP2C9 substrate exposure and an increased risk of toxicity Details Nitisinone Meloxicam Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Nitisinone Meloxicam Injection Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Nitisinone Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details Nitisinone Meropenem Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Meropenem Injection Merrem® Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details Nitisinone Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Nitisinone Methotrexate Injection Abitrexate® Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Nitisinone Oseltamivir Tamiflu Increased OAT1 or OAT3 substrate exposure and an increased risk of OAT1 or OAT3 substrate-related adverse effects Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.